{"doi":"10.1073/pnas.0810402106","title":"Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer","abstract":"<jats:p>\n                    Elevated MET receptor tyrosine kinase correlates with poor outcome in breast cancer, yet the reasons for this are poorly understood. We thus generated a transgenic mouse model targeting expression of an oncogenic Met receptor (Met\n                    <jats:sup>mt</jats:sup>\n                    ) to the mammary epithelium. We show that Met\n                    <jats:sup>mt</jats:sup>\n                    induces mammary tumors with multiple phenotypes. These reflect tumor subtypes with gene expression and immunostaining profiles sharing similarities to human basal and luminal breast cancers. Within the basal subtype, Met\n                    <jats:sup>mt</jats:sup>\n                    induces tumors with signatures of WNT and epithelial to mesenchymal transition (EMT). Among human breast cancers, MET is primarily elevated in basal and ERBB2-positive subtypes with poor prognosis, and we show that MET, together with EMT marker, SNAIL, are highly predictive of poor prognosis in lymph node-negative patients. By generating a unique mouse model in which the Met receptor tyrosine kinase is expressed in the mammary epithelium, along with the examination of MET expression in human breast cancer, we have established a specific link between MET and basal breast cancer. This work identifies basal breast cancers and, additionally, poor-outcome breast cancers, as those that may benefit from anti-MET receptor therapies.\n                  </jats:p>","journal":"Proceedings of the National Academy of Sciences","year":2009,"id":598272,"datarank":0.793995723708674,"base_score":5.293304824724492,"endowment":5.293304824724492,"self_citation_contribution":0.793995723708674,"citation_network_contribution":0.0,"self_endowment_contribution":0.793995723708674,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":198,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":707688,"name":"Robert Lesurf","orcid":"0000-0001-7095-1491","position":1,"is_corresponding":false},{"id":1532925,"name":"Stephanie Petkiewicz","orcid":null,"position":2,"is_corresponding":false},{"id":1532926,"name":"Frances P. O'Malley","orcid":null,"position":3,"is_corresponding":false},{"id":1532927,"name":"Dushanthi Pinnaduwage","orcid":null,"position":4,"is_corresponding":false},{"id":55303,"name":"Irene L. Andrulis","orcid":"0000-0002-4226-6435","position":5,"is_corresponding":false},{"id":331673,"name":"Shelley B. Bull","orcid":"0000-0002-3280-7154","position":6,"is_corresponding":false},{"id":1532928,"name":"Naila Chughtai","orcid":null,"position":7,"is_corresponding":false},{"id":842336,"name":"Dongmei Zuo","orcid":"0000-0001-8701-9238","position":8,"is_corresponding":false},{"id":444470,"name":"Margarita Souleimanova","orcid":null,"position":9,"is_corresponding":false},{"id":1532929,"name":"David Germain","orcid":null,"position":10,"is_corresponding":false},{"id":1532930,"name":"Atilla Omeroglu","orcid":null,"position":11,"is_corresponding":false},{"id":469089,"name":"Robert D. Cardiff","orcid":"0000-0003-3088-8816","position":12,"is_corresponding":false},{"id":907955,"name":"Michael Hallett","orcid":"0000-0001-6738-6786","position":13,"is_corresponding":false},{"id":234999,"name":"Morag Park","orcid":"0000-0001-5400-606X","position":14,"is_corresponding":false},{"id":1532923,"name":"Marisa G. Ponzo","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer","abstract":"<jats:p>\n                    Elevated MET receptor tyrosine kinase correlates with poor outcome in breast cancer, yet the reasons for this are poorly understood. We thus generated a transgenic mouse model targeting expression of an oncogenic Met receptor (Met\n                    <jats:sup>mt</jats:sup>\n                    ) to the mammary epithelium. We show that Met\n                    <jats:sup>mt</jats:sup>\n                    induces mammary tumors with multiple phenotypes. These reflect tumor subtypes with gene expression and immunostaining profiles sharing similarities to human basal and luminal breast cancers. Within the basal subtype, Met\n                    <jats:sup>mt</jats:sup>\n                    induces tumors with signatures of WNT and epithelial to mesenchymal transition (EMT). Among human breast cancers, MET is primarily elevated in basal and ERBB2-positive subtypes with poor prognosis, and we show that MET, together with EMT marker, SNAIL, are highly predictive of poor prognosis in lymph node-negative patients. By generating a unique mouse model in which the Met receptor tyrosine kinase is expressed in the mammary epithelium, along with the examination of MET expression in human breast cancer, we have established a specific link between MET and basal breast cancer. This work identifies basal breast cancers and, additionally, poor-outcome breast cancers, as those that may benefit from anti-MET receptor therapies.\n                  </jats:p>","is_dataset_classified":null,"base_score":5.293304824724492,"endowment":5.293304824724492,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19617568","pmcid":"PMC2722321","openalex_id":"https://openalex.org/W2158563134","authors":[],"funders":[],"total_grants":0,"fwci":7.5389,"citation_percentile":0.98120901,"influential_citations":0,"citation_trend":[{"year":2012,"count":18},{"year":2013,"count":23},{"year":2014,"count":20},{"year":2015,"count":20},{"year":2016,"count":11},{"year":2017,"count":9},{"year":2018,"count":11},{"year":2019,"count":7},{"year":2020,"count":9},{"year":2021,"count":10},{"year":2022,"count":9},{"year":2023,"count":6},{"year":2024,"count":3},{"year":2025,"count":4},{"year":2026,"count":2}],"oa_status":"bronze","license":null,"oa_locations":[{"url":"https://www.pnas.org/content/pnas/106/31/12903.full.pdf","host_type":"journal"},{"url":"https://www.pnas.org/content/pnas/106/31/12903.full.pdf","host_type":"publisher"},{"url":"https://pnas.org/doi/pdf/10.1073/pnas.0810402106","host_type":"publisher"},{"url":"https://doi.org/10.1073/pnas.0810402106","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/19617568","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2722321","host_type":"repository"}],"fields_of_study":["Cancer Cells and Metastasis","Breast Cancer Treatment Studies","HER2/EGFR in Cancer Research"],"mesh_terms":["Snail Family Transcription Factors","Animals","Breast Neoplasms","Epithelium","Humans","Immunohistochemistry","Mammary Tumor Virus, Mouse","Mammary Neoplasms, Experimental","Mesoderm","Mice, Transgenic","Phosphorylation","Prognosis","Transcription Factors","Proto-Oncogene Proteins c-met","Mice"],"keywords":["Oncology","Breast cancer","Internal medicine","Medicine","Human breast","Basal (medicine)","Cancer","Mammary tumor","Cancer research"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"geo"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-28T15:23:44.665055Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}